Pozen shares slide after FDA questions study for aspirin combo – FierceBiotech

Just three months after offering positive top-line Phase III data on PA32540, its combo of immediate-release omeprazole and a 325 mg dose of delayed-release aspirin designed to prevent ulcers among high-risk cardio patients, the biotech …

Leave a Reply

Your email address will not be published. Required fields are marked *

*